Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Advises against long-term COX-2 inhibitor use in renal disease; leaves open metabolite-specific targeting for future research.
PURPOSE OF REVIEW: This review highlights recent studies examining the expression and function of cyclooxygenase-2 and its metabolites in the kidney. RECENT FINDINGS: Expression of cyclooxygenase-2 is regulated by both physiologic and pathophysiologic perturbations, with volume depletion upregulating macula-densa expression and volume expansion upregulating medullary expression. Macula densa cyclooxygenase-2 is a modulator of juxtaglomerular renin expression, and there is increasing evidence that cyclooxygenase-2 expression is modulated by multiple components of the renin-angiotensin system, including angiotensin II, through both AT1 and AT2 receptors. There are also indications that macula densa cyclooxygenase-2 expression may be regulated by the prorenin/renin receptor. Medullary cyclooxygenase-2 metabolites modulate salt and water excretion, and cyclooxygenase-2 inhibitors lead to sodium and volume retention and may raise blood pressure. There is also increasing evidence that cyclooxygenase-2 expression increases in progressive renal injury. Given their cardiovascular and renal side effects, cyclooxygenase-2 inhibitors are not a feasible intervention for long-term therapy against progressive renal damage, but further delineation of the downstream receptors and synthases involved may provide therapeutic targets. SUMMARY: Recent studies have highlighted the important role that cyclooxygenase-2 metabolites play both in regulation of normal renal function and as potential mediators of acute and chronic renal injury.
No takes yet. Share an insight, caveat, or question.
Raymond C. Harris (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: